ChemotherapyPhase 3 trialInvestigational
MM-398
Generic name: naptumomab estafenatox
How it works
MM-398 is a formulation of irinotecan that is designed to be more easily absorbed by cancer cells, causing cell death.
Cancer types
Pancreatic Cancer— All patients
Efficacy
In clinical trials, MM-398 in combination with 5-fluorouracil and leucovorin improved median overall survival to approximately 6.1 months compared to 5-fluorouracil and leucovorin alone.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.